Please use this identifier to cite or link to this item:
Title: Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study.
Austin Authors: Ray, Jason Charles;Dalic, Linda J ;Baker, Josephine;Cheng, Shuli;Hutton, Elspeth Jane;Matharu, Manjit
Affiliation: Department of Neurology, Alfred Health, Melbourne, Victoria, Australia.;Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Department of Neurology, Alfred Health, Melbourne, Victoria, Australia.
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.
University College London Queen Square Institute of Neurology, London, UK.;National Hospital for Neurology and Neurosurgery, London, UK.
Issue Date: 2024
Date: 2024
Publication information: BMJ Neurology Open 2024; 6(1)
Abstract: Clinical trials show that calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are effective preventative treatments for chronic migraine. Their efficacy over longer time periods and in cohorts originally excluded from trials remains uncertain. This study aims to explore the impact of CGRP mAbs in an Australian real-life setting. A multicentre cohort study was performed in the tertiary headache clinics of the Alfred and Austin Hospitals, Melbourne, Australia. Patients were commenced on a CGRP mAb for chronic migraine and asked to keep a headache diary, recorded at 3 monthly appointments for 12 months. Primary outcome was a ≥50% reduction in monthly headache days (MHD). From a population of 105 patients, 90 patients commenced galcanezumab and 15 commenced fremanezumab. The ≥50% responder rate of the cohort was 52.4% after 3 months. Over 12 months follow-up, 25.7% of the cohort ceased due to a lack of efficacy and 16.2% ceased due to an adverse event. There was no difference in response or cessation between medications. There was poor agreement in 3-month and 12-month response rates (Cohen's κ=0.130; p=0.171). On subgroup analysis, continuous headache at baseline and number of trialled preventative treatments were the only factors associated with efficacy. CGRP mAbs were associated with sustained reductions in MHD over 12-month follow-up in patients with resistant migraine in Australia. Further studies are required to determine treatment options for patients with continuous headache. Poor agreement between outcomes at 3 and 12 months highlights the need to assess some patients at later timepoints.
DOI: 10.1136/bmjno-2023-000547
ORCID: 0000-0003-4833-5507
Journal: BMJ Neurology Open
Start page: e000547
PubMed URL: 38268750
ISSN: 2632-6140
Type: Journal Article
Subjects: migraine
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 18, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.